402 related articles for article (PubMed ID: 32792920)
21. Therapeutic role of inflammasome inhibitors in neurodegenerative disorders.
Lahooti B; Chhibber T; Bagchi S; Varahachalam SP; Jayant RD
Brain Behav Immun; 2021 Jan; 91():771-783. PubMed ID: 33157255
[TBL] [Abstract][Full Text] [Related]
22. Targeting NLRP3 inflammasome for neurodegenerative disorders.
Yao J; Wang Z; Song W; Zhang Y
Mol Psychiatry; 2023 Nov; 28(11):4512-4527. PubMed ID: 37670126
[TBL] [Abstract][Full Text] [Related]
23. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson's disease: mechanisms and therapeutic implications.
Soraci L; Gambuzza ME; Biscetti L; Laganà P; Lo Russo C; Buda A; Barresi G; Corsonello A; Lattanzio F; Lorello G; Filippelli G; Marino S
J Neurol; 2023 Mar; 270(3):1346-1360. PubMed ID: 36460875
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 Tat Primes and Activates Microglial NLRP3 Inflammasome-Mediated Neuroinflammation.
Chivero ET; Guo ML; Periyasamy P; Liao K; Callen SE; Buch S
J Neurosci; 2017 Mar; 37(13):3599-3609. PubMed ID: 28270571
[TBL] [Abstract][Full Text] [Related]
25. Edaravone Attenuates the Proinflammatory Response in Amyloid-β-Treated Microglia by Inhibiting NLRP3 Inflammasome-Mediated IL-1β Secretion.
Wang HM; Zhang T; Huang JK; Xiang JY; Chen JJ; Fu JL; Zhao YW
Cell Physiol Biochem; 2017; 43(3):1113-1125. PubMed ID: 28977782
[TBL] [Abstract][Full Text] [Related]
26. Sendai Virus V Protein Inhibits the Secretion of Interleukin-1β by Preventing NLRP3 Inflammasome Assembly.
Komatsu T; Tanaka Y; Kitagawa Y; Koide N; Naiki Y; Morita N; Gotoh B; Yokochi T
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021903
[TBL] [Abstract][Full Text] [Related]
27. A novel strategy for bioactive natural products targeting NLRP3 inflammasome in Alzheimer's disease.
Yang Z; Liu J; Wei S; Deng J; Feng X; Liu S; Liu M
Front Pharmacol; 2022; 13():1077222. PubMed ID: 36699095
[TBL] [Abstract][Full Text] [Related]
28. The neuroprotection of progesterone against Aβ-induced NLRP3-Caspase-1 inflammasome activation via enhancing autophagy in astrocytes.
Hong Y; Liu Y; Yu D; Wang M; Hou Y
Int Immunopharmacol; 2019 Sep; 74():105669. PubMed ID: 31176046
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease.
Thawkar BS; Kaur G
J Neuroimmunol; 2019 Jan; 326():62-74. PubMed ID: 30502599
[TBL] [Abstract][Full Text] [Related]
30. Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3.
Zhu J; Hu Z; Han X; Wang D; Jiang Q; Ding J; Xiao M; Wang C; Lu M; Hu G
Cell Death Differ; 2018 Nov; 25(11):2037-2049. PubMed ID: 29786071
[TBL] [Abstract][Full Text] [Related]
31. PPARß/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease.
Chen L; Xue L; Zheng J; Tian X; Zhang Y; Tong Q
Behav Brain Res; 2019 Jan; 356():483-489. PubMed ID: 29885849
[TBL] [Abstract][Full Text] [Related]
32. From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?
Si XL; Fang YJ; Li LF; Gu LY; Yin XZ; Jun-Tian ; Yan YP; Pu JL; Zhang BR
Exp Neurol; 2021 Feb; 336():113525. PubMed ID: 33161049
[TBL] [Abstract][Full Text] [Related]
33. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production.
Yu X; Lan P; Hou X; Han Q; Lu N; Li T; Jiao C; Zhang J; Zhang C; Tian Z
J Hepatol; 2017 Apr; 66(4):693-702. PubMed ID: 28027970
[TBL] [Abstract][Full Text] [Related]
34. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Han X; Sun S; Sun Y; Song Q; Zhu J; Song N; Chen M; Sun T; Xia M; Ding J; Lu M; Yao H; Hu G
Autophagy; 2019 Nov; 15(11):1860-1881. PubMed ID: 30966861
[TBL] [Abstract][Full Text] [Related]
35. Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases.
Pellegrini C; Fornai M; Antonioli L; Blandizzi C; Calderone V
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31200447
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.
Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S
Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768
[TBL] [Abstract][Full Text] [Related]
37. The Role of NLRP3 Inflammasome in Alzheimer's Disease and Potential Therapeutic Targets.
Liang T; Zhang Y; Wu S; Chen Q; Wang L
Front Pharmacol; 2022; 13():845185. PubMed ID: 35250595
[TBL] [Abstract][Full Text] [Related]
38. Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo.
Stancu IC; Cremers N; Vanrusselt H; Couturier J; Vanoosthuyse A; Kessels S; Lodder C; Brône B; Huaux F; Octave JN; Terwel D; Dewachter I
Acta Neuropathol; 2019 Apr; 137(4):599-617. PubMed ID: 30721409
[TBL] [Abstract][Full Text] [Related]
39. Neurodegenerative Disease and the NLRP3 Inflammasome.
Holbrook JA; Jarosz-Griffiths HH; Caseley E; Lara-Reyna S; Poulter JA; Williams-Gray CH; Peckham D; McDermott MF
Front Pharmacol; 2021; 12():643254. PubMed ID: 33776778
[TBL] [Abstract][Full Text] [Related]
40. NLRP3 inflammasome in NMDA-induced retinal excitotoxicity.
Tsoka P; Barbisan PR; Kataoka K; Chen XN; Tian B; Bouzika P; Miller JW; Paschalis EI; Vavvas DG
Exp Eye Res; 2019 Apr; 181():136-144. PubMed ID: 30707890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
